Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization
A subset of cells within solid tumors become highly enlarged and enter a state of dormancy (sustained proliferation arrest) in response to anticancer treatment. Although dormant cancer cells might be scored as “dead” in conventional preclinical assays, they remain viable, secrete growth-promoting fa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115892/ https://www.ncbi.nlm.nih.gov/pubmed/30071623 http://dx.doi.org/10.3390/cancers10080255 |
_version_ | 1783351485885579264 |
---|---|
author | Mirzayans, Razmik Andrais, Bonnie Murray, David |
author_facet | Mirzayans, Razmik Andrais, Bonnie Murray, David |
author_sort | Mirzayans, Razmik |
collection | PubMed |
description | A subset of cells within solid tumors become highly enlarged and enter a state of dormancy (sustained proliferation arrest) in response to anticancer treatment. Although dormant cancer cells might be scored as “dead” in conventional preclinical assays, they remain viable, secrete growth-promoting factors, and can give rise to progeny with stem cell-like properties. Furthermore, cancer cells exhibiting features of apoptosis (e.g., caspase-3 activation) following genotoxic stress can undergo a reversal process called anastasis and survive. Consistent with these observations, single-cell analysis of adherent cultures (solid tumor-derived cell lines with differing p53 status) has demonstrated that virtually all cells—irrespective of their size and morphology—that remain adherent to the culture dish for a long time (weeks) after treatment with anticancer agents exhibit the ability to metabolize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- tetrazolium bromide (MTT). The purpose of this commentary is to briefly review these findings and discuss the significance of single-cell (versus population averaged) observation methods for assessment of cancer cell viability and metabolic activity. |
format | Online Article Text |
id | pubmed-6115892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61158922018-08-31 Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization Mirzayans, Razmik Andrais, Bonnie Murray, David Cancers (Basel) Commentary A subset of cells within solid tumors become highly enlarged and enter a state of dormancy (sustained proliferation arrest) in response to anticancer treatment. Although dormant cancer cells might be scored as “dead” in conventional preclinical assays, they remain viable, secrete growth-promoting factors, and can give rise to progeny with stem cell-like properties. Furthermore, cancer cells exhibiting features of apoptosis (e.g., caspase-3 activation) following genotoxic stress can undergo a reversal process called anastasis and survive. Consistent with these observations, single-cell analysis of adherent cultures (solid tumor-derived cell lines with differing p53 status) has demonstrated that virtually all cells—irrespective of their size and morphology—that remain adherent to the culture dish for a long time (weeks) after treatment with anticancer agents exhibit the ability to metabolize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl- tetrazolium bromide (MTT). The purpose of this commentary is to briefly review these findings and discuss the significance of single-cell (versus population averaged) observation methods for assessment of cancer cell viability and metabolic activity. MDPI 2018-08-01 /pmc/articles/PMC6115892/ /pubmed/30071623 http://dx.doi.org/10.3390/cancers10080255 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Commentary Mirzayans, Razmik Andrais, Bonnie Murray, David Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title | Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title_full | Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title_fullStr | Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title_full_unstemmed | Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title_short | Viability Assessment Following Anticancer Treatment Requires Single-Cell Visualization |
title_sort | viability assessment following anticancer treatment requires single-cell visualization |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115892/ https://www.ncbi.nlm.nih.gov/pubmed/30071623 http://dx.doi.org/10.3390/cancers10080255 |
work_keys_str_mv | AT mirzayansrazmik viabilityassessmentfollowinganticancertreatmentrequiressinglecellvisualization AT andraisbonnie viabilityassessmentfollowinganticancertreatmentrequiressinglecellvisualization AT murraydavid viabilityassessmentfollowinganticancertreatmentrequiressinglecellvisualization |